A practical reference on refrigeration: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-15 and is reviewed periodically as new material appears.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or solid form |
| Solubility | Sparingly soluble in water | May require buffer or pH adjustment |
| Typical storage temperature | 2–8 °C | Refrigerated; protect from light |
| Common analytical method | RP-HPLC | For purity and impurity profiling |
| Molecular weight | Approximately 4813 Da | For the peptide backbone; varies with counterions |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Formica polyctena, among other ant species, constructs nests that maintain a relatively constant interior temperature that aids in the development of larvae. The ants maintain the nest temperature by choosing the location, nest materials, controlling ventilation and maintaining the heat from solar radiation, worker activity and metabolism, and in some moist nests, microbial activity in the nest materials. Some ant species, such as those that use natural cavities, can be opportunistic and make use of the controlled micro-climate provided inside human dwellings and other artificial structures to house their colonies and nest structures.
=== Economic miracle === The West German Wirtschaftswunder ("economic miracle", coined by The Times) began in 1950. This improvement was sustained by the currency reform of 1948 which replaced the Reichsmark with the Deutsche Mark and halted rampant inflation. The Allied dismantling of the West German coal and steel industry finally ended in 1950.
==== MeSH D12.776.624.664.700 – proto-oncogene proteins ==== MeSH D12.776.624.664.700.100 – cyclin d1 MeSH D12.776.624.664.700.110 – fibroblast growth factor 4 MeSH D12.776.624.664.700.112 – fibroblast growth factor 6 MeSH D12.776.624.664.700.114 – fms-like tyrosine kinase 3 MeSH D12.776.624.664.700.120 – receptor, fibroblast growth factor, type 3 MeSH D12.776.624.664.700.130 – muts homolog 2 protein MeSH D12.776.624.664.700.148 – myeloid-lymphoid leukemia protein MeSH D12.776.624.664.700.167 – proto-oncogene proteins c-abl MeSH D12.776.624.664.700.168 – proto-oncogene proteins c-akt MeSH D12.776.624.664.700.169 – proto-oncogene proteins c-bcl-2 MeSH D12.776.624.664.700.170 – proto-oncogene proteins c-bcl-6 MeSH D12.776.624.664.700.171 – proto-oncogene proteins c-bcr MeSH D12.776.624.664.700.172 – proto-oncogene proteins c-cbl MeSH D12.776.624.664.700.174 – proto-oncogene proteins c-crk MeSH D12.776.624.664.700.175 – proto-oncogene proteins c-ets MeSH D12.776.624.664.700.175.100 – proto-oncogene protein c-ets-1 MeSH D12.776.624.664.700.175.200 – proto-oncogene protein c-ets-2 MeSH D12.776.624.664.700.175.400 – proto-oncogene protein c-fli-1 MeSH D12.776.624.664.700.175.600 – ternary complex factors MeSH D12.776.624.664.700.175.600.100 – ets-domain protein elk-1 MeSH D12.776.624.664.700.175.600.300 – ets-domain protein elk-4 MeSH D12.776.624.664.700.177 – proto-oncogene proteins c-fes MeSH D12.776.624.664.700.179 – proto-oncogene proteins c-fos MeSH D12.776.624.664.700.180 – proto-oncogene proteins c-fyn MeSH D12.776.624.664.700.181 – proto-oncogene proteins c-hck MeSH D12.776.624.664.700.182 – proto-oncogene proteins c-jun MeSH D12.776.624.664.700.183 – proto-oncogene proteins c-kit MeSH D12.776.624.664.700.184 – proto-oncogene proteins c-maf MeSH D12.776.624.664.700.185 – proto-oncogene proteins c-mdm2 MeSH D12.776.624.664.700.186 – proto-oncogene proteins c-met MeSH D12.776.624.664.700.187 – proto-oncogene proteins c-mos MeSH D12.776.624.664.700.188 – proto-oncogene proteins c-myb MeSH D12.776.624.664.700.189 – proto-oncogene proteins c-myc MeSH D12.776.624.664.700.191 – proto-oncogene proteins c-pim-1 MeSH D12.776.624.664.700.192 – proto-oncogene proteins c-rel MeSH D12.776.624.664.700.194 – proto-oncogene proteins c-ret MeSH D12.776.624.664.700.195 – proto-oncogene proteins c-sis MeSH D12.776.624.664.700.198 – proto-oncogene proteins c-vav MeSH D12.776.624.664.700.199 – proto-oncogene proteins c-yes MeSH D12.776.624.664.700.200 – proto-oncogene proteins p21(ras) MeSH D12.776.624.664.700.202 – proto-oncogene proteins pp60(c-src) MeSH D12.776.624.664.700.204 – raf kinases MeSH D12.776.624.664.700.204.200 – proto-oncogene proteins b-raf MeSH D12.776.624.664.700.204.500 – proto-oncogene proteins c-raf MeSH D12.776.624.664.700.205 – RNA-binding protein EWS MeSH D12.776.624.664.700.250 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D12.776.624.664.700.642 – receptor, erbb-2 MeSH D12.776.624.664.700.790 – receptor, erbb-3 MeSH D12.776.624.664.700.800 – receptor, macrophage colony-stimulating factor MeSH D12.776.624.664.700.830 – receptors, thyroid hormone MeSH D12.776.624.664.700.830.500 – thyroid hormone receptors alpha MeSH D12.776.624.664.700.830.750 – thyroid hormone receptors beta MeSH D12.776.624.664.700.915 – RNA-binding protein FUS MeSH D12.776.624.664.700.957 – stathmin MeSH D12.776.624.664.700.967 – wnt1 protein MeSH D12.776.624.664.700.978 – wnt2 protein
5-HT2 receptors are G protein-coupled receptors that can regulate cellular signaling in the absence of a ligand. This can be explained by a two-state model (Figure 2) where the receptor is in equilibrium between two states, an active state (R*) and an inactive state (R). Basal effector activity is defined, in part, by the absolute level of (R*), which will increase along with increasing receptor density. Ligands that preferentially bind to and stabilize the R state are termed inverse agonists and reduce the effector activity. Agonists preferentially bind to and stabilize the R* state, thereby increasing effector activity. Neutral antagonists show equal affinity for both conformations and do not alter the equilibrium between the two states, however they occupy the receptor and can block the effect of both agonists and inverse agonists. 5-HT2C and 5-HT2A receptors have a similar amino acid sequence homology, with ~50% overall sequence identity and ~80% within the TM domains, resulting in a similar pharmacological profile for the two receptors. Both receptors couple the same cellular signal transduction pathways, PLC and PLA2, that lead to an accumulation of inositol phosphate and Ca2+ within the postsynaptic cell. The 5-HT2C receptors are the only G-protein coupled receptors known to undergo a post-transcriptional process of RNA editing. The 5-HT2C receptor gene is found on the X-chromosome, Xq24. This gene product undergoes an RNA editing process leading to a decrease in agonist binding affinity, however antagonist binding remains unaltered.
== Effect of glycosylation on activity == α-Antithrombin and β-antithrombin differ in their affinity for heparin. The difference in dissociation constant between the two is threefold for the pentasaccharide shown in Figure 3 and greater than tenfold for full length heparin, with β-antithrombin having a higher affinity. The higher affinity of β-antithrombin is thought to be due to the increased rate at which subsequent conformational changes occur within the protein upon initial heparin binding. For α-antithrombin, the additional glycosylation at Asn-135 is not thought to interfere with initial heparin binding, but rather to inhibit any resulting conformational changes. Even though it is present at only 5–10% the levels of α-antithrombin, due to its increased heparin affinity, it is thought that β-antithrombin is more important than α-antithrombin in controlling thrombogenic events resulting from tissue injury. Indeed, thrombin inhibition after injury to the aorta has been attributed solely to β-antithrombin.
Sources: en.wikipedia.org
In November 2015, an FDA Advisory Committee discussed the risks and benefits of fluoroquinolones for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated UTIs based on new safety information. The new information focused on two or more side effects occurring at the same time and causing the potential for irreversible impairment. The advisory committee concluded that the serious risks associated with the use of fluoroquinolones for these types of uncomplicated infections generally outweighed the benefits for patients with other treatment options. The 21-member joint committee overwhelmingly recommended stronger label warnings on the containers because of rare but sometimes devastating side effects. On 12 May 2016, the FDA issued a drug safety communication advising that fluoroquinolones should be reserved for these conditions only when no other options are available due to potentially permanent, disabling side effects occurring together. The drug safety communication also announced the required labeling updates to reflect this new safety information. The FDA put out another label change in July 2017, strengthening the warnings about potentially disabling adverse effects and limiting use of these drugs to second-line treatments for acute sinusitis, acute bronchitis, and uncomplicated UTIs.
The asymmetric atom is called a chirality center, a type of stereocenter. A chirality center is also called a chiral center or an asymmetric center. Some sources use the terms stereocenter, stereogenic center, stereogenic atom or stereogen to refer exclusively to a chirality center, while others use the terms more broadly to refer also to centers that result in diastereomers (stereoisomers that are not enantiomers). Compounds that contain exactly one (or any odd number) of asymmetric atoms are always chiral. However, compounds that contain an even number of asymmetric atoms sometimes lack chirality because they are arranged in mirror-symmetric pairs, and are known as meso compounds. For instance, meso tartaric acid (shown on the right) has two asymmetric carbon atoms, but it does not exhibit enantiomerism because there is a mirror symmetry plane. Conversely, there exist forms of chirality that do not require asymmetric atoms, such as axial, planar, and helical chirality. Even though a chiral molecule lacks reflection (Cs) and rotoreflection symmetries (S2n), it can have other molecular symmetries, and its symmetry is described by one of the chiral point groups: Cn, Dn, T, O, or I. For example, hydrogen peroxide is chiral and has C2 (two-fold rotational) symmetry. A common chiral case is the point group C1, meaning no symmetries, which is the case for lactic acid.
==== Other activities ==== Bicalutamide has been found to act as an inhibitor or inducer of certain cytochrome P450 enzymes including CYP3A4, CYP2C9, CYP2C19, and CYP2D6 in preclinical research, but no evidence of this has been found in humans treated with up to 150 mg/day. It has also been identified in vitro as a strong inhibitor of CYP27A1 (cholesterol 27-hydroxylase) and as an inhibitor of CYP46A1 (cholesterol 24-hydroxylase), but this has yet to be assessed or confirmed in vivo or in humans and the clinical significance remains unknown. Bicalutamide has been found to be a P-glycoprotein (ABCB1) inhibitor. Like other first-generation NSAAs and enzalutamide, it has been found to act as a weak non-competitive inhibitor of GABAA receptor-mediated currents in vitro (IC50 = 5.2 μM). However, unlike enzalutamide, bicalutamide has not been found to be associated with seizures or other related adverse central effects, so the clinical relevance of this finding is uncertain.
Tautomerism – A base is changed by the repositioning of a hydrogen atom, altering the hydrogen bonding pattern of that base, resulting in incorrect base pairing during replication. Theoretical results suggest that proton tunneling is an important factor in the spontaneous creation of GC tautomers. Depurination – Loss of a purine base (A or G) to form an apurinic site (AP site). Deamination – Hydrolysis changes a normal base to an atypical base containing a keto group in place of the original amine group. Examples include C → U and A → HX (hypoxanthine), which can be corrected by DNA repair mechanisms; and 5MeC (5-methylcytosine) → T, which is less likely to be detected as a mutation because thymine is a normal DNA base. Slipped strand mispairing – Denaturation of the new strand from the template during replication, followed by renaturation in a different spot ("slipping"). This can lead to insertions or deletions.
Sources: en.wikipedia.org
=== Geelong: 2005–2008 === At the start of 2006, he moved out of his Werribee home and moved to Geelong to live with teammates Corey Enright and Henry Playfair, with whom he would later go on to start a personal training organisation. He then set his sights on playing a senior game for Geelong and, after playing in the team that had earlier won the pre-season cup, he was selected to play in round 5. Only minutes into his debut, on 29 April against the Sydney Swans, he broke his arm and only played eight games for the year. After a solid pre-season, he played the first five games of 2007 before being omitted and then broke his wrist while playing for the Geelong VFL side on 8 July 2007. As a result, Prismall was unable to play for several weeks but recovered in time to play finals for the VFL side. In 2008, Prismall played in 11 home and away games and was selected to play in the qualifying final against St Kilda on 7 September 2008, which was to be his 25th game and finals debut. However, midway through the first quarter, he was stretchered off and did not return after landing awkwardly and badly injuring his right knee. It was later confirmed that he would have to undergo a full knee reconstruction after scans revealed a ruptured anterior cruciate ligament. After the 2008 season, Prismall declined the new two-year contract offered to him by Geelong and asked the club to be traded to get a better chance of playing more regularly in the AFL. On the final day of trade week, he was traded to the Essendon Football Club for national draft pick number 39.
The field of plastic surgery was brought to Europe, specifically Catania, in the fifteenth century, when Gustavo Branca successfully completed an ancient Indian method of reconstructive rhinoplasty. Plastic surgery continued to grow as a field across the continent, and the birth of this field is likely related to nose amputation as punishment.
The two substrates of this enzyme are scytalone and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are naphthalene-1,3,6,8-tetrol, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is scytalone:NADP+ Delta5-oxidoreductase.
==== Season 1 ==== The following table represents viewership data for each episode's airing on The CW, as DC Universe did not release viewership information. The pilot episode was tied for the second-best series debut on The CW for the 2019–20 television season with Nancy Drew after Batwoman, and was the best summer series premiere on the network since Whose Line Is It Anyway? season nine in 2013. Through the first seven episodes of the season, Stargirl was averaging a 0.2 rating for adults 18–49 and close to 1 million initial viewers per episode, which was "on par" with The CW's Arrowverse series.
=== Effect of parental age and temperature === Offspring produced by older beetles have shorter larval stages than those produced by younger beetles. Larvae from the older beetles also show a rapid weight increase at an earlier age than those from young parents. At 25 °C, the larval stage was shortened, the number of larval molts decreased, and the durations of adult life decreased when parental age increased, compared to the beetles at 30 °C. Another study found that at 20°, 25°, and 30 °C, parental age does not have any effect on the duration of the egg stage, or the weights of the eggs. However, the amount of hatched eggs decreased when parental age increased. When eggs were laid during the first two months after emergence, approximately 90% of the eggs hatched. When they were laid after four months, only about 50% hatched. It was found that larvae from young parents grow at a slower rate, compared to larvae produced by the same parents, nine weeks earlier. At 30 °C, there were no other effects of parental age on the larvae. At 20° and 25 °C, the larvae from young parents required significantly more time to complete development, and had more molts compared to the larvae from the same parents after they had aged one more or longer. The duration of adult life decreased when parental age increased.
Sources: en.wikipedia.org
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.
Typically refrigerated at 2–8 °C. Protect from light and avoid freezing.
Deamidation, oxidation, and aggregation products. SEC and ion-exchange chromatography are used.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.